IYH - iShares U.S. Healthcare ETF
| Assets | $2.59B |
| NAV | $262.66 |
| Expense Ratio | 0.43% |
| PE Ratio | 27.86 |
| Beta (5Y) | 0.77 |
| Dividend (ttm) | $2.91 |
| Dividend Yield | 1.11% |
| Ex-Dividend Date | Mar 25, 2021 |
| 1-Year Return | - |
| Trading Day | April 20 |
| Last Price | $263.66 |
| Previous Close | $262.65 |
| Change ($) | 1.01 |
| Change (%) | 0.38% |
| Day's Open | 262.29 |
| Day's Range | 262.29 - 264.00 |
| Day's Volume | 41,050 |
| 52-Week Range | 203.02 - 264.00 |
Fund Description
The investment seeks to track the investment results of the Dow Jones U.S. Health Care Index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.
| Asset Class Equity | Sector Biotech |
| Region North America | Inception Date Jun 12, 2000 |
| Exchange NYSEARCA | Ticker Symbol IYH |
| Index Tracked Dow Jones U.S. Health Care Index | |
Top 10 Holdings
45.37% of assets| Name | Symbol | Weight |
|---|---|---|
| Johnson & Johnson | JNJ | 8.86% |
| UnitedHealth | UNH | 7.12% |
| Abbott Laboratories | ABT | 4.38% |
| Pfizer | PFE | 4.13% |
| Merck | MRK | 3.97% |
| AbbVie | ABBV | 3.83% |
| Thermo Fisher Scientific | TMO | 3.78% |
| Medtronic | MDT | 3.35% |
| Eli Lilly | LLY | 2.99% |
| Amgen | AMGN | 2.95% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 25, 2021 | $0.661 | Mar 31, 2021 |
| Dec 14, 2020 | $0.757 | Dec 18, 2020 |
| Sep 23, 2020 | $0.889 | Sep 29, 2020 |
| Jun 15, 2020 | $0.603 | Jun 19, 2020 |
| Mar 25, 2020 | $0.613 | Mar 31, 2020 |
| Dec 16, 2019 | $0.643 | Dec 20, 2019 |
Investment company Rainey & Randall Investment Management Inc. (Current Portfolio) buys iShares 0-5 Year TIPS Bond ETF, Medical Properties Trust Inc, Facebook Inc, VanEck Vectors High Yield Muni ETF, iS...
UnitedHealth agreed to buy Change Healthcare for $7.84 billion in cash.
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
We have highlighted one ETF and one stock from the four sectors that could make great plays as the earnings season unfolds.
The halt in stimulus talks has made investors jittery, resulting in a flight to defensive sectors like utilities, real estate, healthcare and consumer staples.
When looking for the best ETFs to buy, diversification is important when selecting the appropriate choices for your investment portfolio. The post The 7 Best ETFs for a Truly Diversified Portfolio ...
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
For people with stable finances, a volatile market can be a great time to invest.
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
Along with molecular testing, antibody testing is gaining immense prominence as economies are struggling to reopen.
While stocks struggled anew on Wednesday, relinquishing most of the gains of the prior day, amid poor data and renewed coronavirus concerns, the healthcare sector had some shining stars. Shares of Johns...
It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.
Investors have shunned healthcare stocks and sector-related ETFs during a U.S. presidential election year, but things might turn out differently this time around.
For the iShares U.S. Healthcare ETF (IYH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $235.37 per unit.
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Income-minded investors who are looking for better dividend growth opportunities can consider targeted exchange traded fund plays to hone in on potentially worthwhile areas, notably those in the healthc...
While all eyes are on the fate of the phase one trade deal between the United States and China, Healthcare sector can forget tension and soar higher in 2020 even if there is no deal.
Final trades: Wendy's, Roku, Tanger, Alibaba, and more
The "Halftime Report" traders give their top stocks to watch for the second half
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
While markets have had a choppy week, 2019 has revealed some outstanding performers in certain underrated sectors. Technology and healthcare have been solid spaces to invest in, despite how the headline...
For the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $219.78 per unit.
For the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $217.98 per unit.
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
For the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $217.51 per unit.
For the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $217.72 per unit.
For the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $216.79 per unit.
For the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $217.09 per unit.
For the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $216.85 per unit.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
or the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $217.06 per unit.
For the iShares U.S. Healthcare ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $216.68 per unit.